Treasurer of the State of North Carolina’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-46,854
Closed -$732K 1035
2024
Q1
$732K Buy
46,854
+320
+0.7% +$4.71K ﹤0.01% 971
2023
Q4
$695K Buy
46,534
+450
+1% +$6.02K ﹤0.01% 983
2023
Q3
$744K Buy
46,084
+230
+0.5% +$6.63K ﹤0.01% 975
2023
Q2
$1.9M Buy
45,854
+690
+2% +$42.8K 0.01% 858
2023
Q1
$2.72M Buy
45,164
+320
+0.7% +$25.6K 0.02% 725
2022
Q4
$3.29M Buy
44,844
+570
+1% +$42.9K 0.02% 633
2022
Q3
$3.36M Buy
44,274
+570
+1% +$44.5K 0.02% 604
2022
Q2
$3.04M Buy
43,704
+5,995
+16% +$452K 0.02% 654
2022
Q1
$3.12M Sell
37,709
-23,372
-38% -$1.72M 0.02% 637
2021
Q4
$4.59M Buy
61,081
+10,692
+21% +$1.07M 0.02% 553
2021
Q3
$5.85M Buy
50,389
+6,979
+16% +$1.06M 0.03% 473
2021
Q2
$9.63M Buy
43,410
+5,120
+13% +$996K 0.06% 324
2021
Q1
$5.06M Sell
38,290
-70
-0.2% -$11.1K 0.03% 496
2020
Q4
$6.64M Buy
38,360
+620
+2% +$84.8K 0.04% 382
2020
Q3
$4.2M Sell
37,740
-750
-2% -$60K 0.03% 474
2020
Q2
$2.28M Buy
+38,490
New +$2.53M 0.02% 630

Other funds holding NVCR

Treasurer of the State of North Carolina's NVCR Position: Q2 2024 in Review

Treasurer of the State of North Carolina sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 46,854 shares — an estimated $732K sold.

Treasurer of the State of North Carolina first reported a position in NVCR in Q2 2020 and held it in 16 quarters. The position peaked at $9.63M in Q2 2021. 237 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

  • Treasurer of the State of North Carolina reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
  • Treasurer of the State of North Carolina sold 46,854 NovoCure shares in Q2 2024, an estimated $732K.
  • Treasurer of the State of North Carolina first reported a position in NovoCure in Q2 2020 and held it in 16 quarters.
  • Treasurer of the State of North Carolina's NovoCure position peaked at $9.63M in Q2 2021.
  • 237 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Treasurer of the State of North Carolina's 13F filing for Q2 2024, filed 14 Aug 2024.